Yasmin (drospirenone/ethinyl estradiol) tablets provide an oral contraceptive regimen consisting of 28 film-coated tablets that contain the ingredients specified for each tablet below: • 21 yellow tablets each containing 3 mg DRSP and 0.03 mg EE • 7 inert white tablets • The inactive ingredients in the yellow tablets are lactose monohydrate NF, corn starch NF, pregelatinized starch NF, povidone 25000 NF, magnesium stearate NF, hypromellose USP, macrogol 6000 NF, titanium dioxide USP, talc USP, ...

Read more

Yasmin (drospirenone/ethinyl estradiol) tablets are available in blister packs. Each blister pack contains 28 film-coated, round, bi-convex tablets in the following order: • 21 yellow tablets each containing 3 mg drospirenone (DRSP) and 0.03 mg ethinyl estradiol (EE) embossed with a “DO” in a regular hexagon on one side • 7 inert white tablets embossed with a “DP” in a regular hexagon on one side Yasmin consists of 28 film-coated, biconvex tablets in the following order: • 21 yellow tablets, each...

Read more

• Take one tablet daily by mouth at the same time every day. • Tablets must be taken in the order directed on the blister pack. 2.1 How to Take Yasmin Take one tablet by mouth at the same time every day. The failure rate may increase when pills are missed or taken incorrectly. To achieve maximum contraceptive effectiveness, Yasmin must be taken as directed, in the order directed on the blister pack. Single missed pills should be taken as soon as remembered. 2.2 How to Start Yasmin Instruct the patient...

Read more

Yasmin is contraindicated in females who are known to have or develop the following conditions: • Renal impairment • Adrenal insufficiency • A high risk of arterial or venous thrombotic diseases. Examples include women who are known to: • Smoke, if over age 35 • Have deep vein thrombosis or pulmonary embolism, now or in the past • Have cerebrovascular disease • Have coronary artery disease • Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacteri...

Read more

• Vascular risks : Stop Yasmin if a thrombotic event occurs. Stop at least 4 weeks before and through 2 weeks after major surgery. Start no earlier than 4 weeks after delivery, in women who are not breastfeeding. COCs containing DRSP may be associated with a higher risk of venous thromboembolism (VTE) than COCs containing levonorgestrel or some other progestins. Before initiating Yasmin in a new COC user or a woman who is switching from a contraceptive that does not contain DRSP, consider the risks ...

Read more

Consult the labeling of all concurrently-used drugs to obtain further information about interactions with hormonal contraceptives or the potential for enzyme alterations . Drugs or herbal products that induce certain enzymes (for example, CYP3A4) may decrease the effectiveness of COCs or increase breakthrough bleeding. Counsel patients to use a back-up or alternative method of contraception when enzyme inducers are used with COCs. 7.1 Effects of Other Drugs on Combined Oral Contraceptives Substance...

Read more

There is no use for contraception in pregnancy; therefore, Yasmin should be discontinued during pregnancy. Epidemiologic studies and meta-analyses have not found an increased risk of genital or non-genital birth defects (including cardiac anomalies and limb-reduction defects) following exposure to CHCs before conception or during early pregnancy. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4 percen...

Read more